3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
604
Carboplatin
372
Paclitaxel
282
Cisplatin
267
Gemcitabine
252
Pemetrexed
193
Bevacizumab
190
Docetaxel
185
Nivolumab
181
Injections
167
Cyclophosphamide
147
atezolizumab
138
Fluorouracil
133
Capecitabine
133
Oxaliplatin
132
Dexamethasone
127
Fulvestrant
113
durvalumab
112
130-nm albumin-bound paclitaxel
110
fludarabine
101
Cetuximab
100
Leucovorin
97
Rituximab
94
venetoclax
90
Lenalidomide
83
enzalutamide
77
Prednisone
76
Azacitidine
74
Irinotecan
72
Ipilimumab
72
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Serotonin 5-HT3 Receptor Antagonists
×
1 year
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled
NCT06780085
2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2
Recruiting
96 enrolled